Repository
How to publish
Resources
FAQs

Show simple item record

SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

dc.contributor.authorRedin, E.
dc.contributor.authorGarmendia, I.
dc.contributor.authorLozano, T.
dc.contributor.authorSerrano, D.
dc.contributor.authorSenent, Y.
dc.contributor.authorRedrado, M.
dc.contributor.authorVillalba, M.
dc.contributor.authorDe Andrea, C. E.
dc.contributor.authorExposito, F.
dc.contributor.authorAjona, D.
dc.contributor.authorOrtiz Espinosa, S.
dc.contributor.authorRemirez, A.
dc.contributor.authorBertolo, C.
dc.contributor.authorSainz, C.
dc.contributor.authorGarcía Pedrero, Juana María 
dc.date.accessioned2021-11-09T07:33:23Z
dc.date.available2021-11-09T07:33:23Z
dc.date.issued2021
dc.identifier.citationJournal for ImmunoTherapy of Cancer, 9(3) (2021); doi:10.1136/jitc-2020-001496
dc.identifier.issn2051-1426
dc.identifier.urihttp://hdl.handle.net/10651/60933
dc.description.sponsorshipThis work has been funded by the Foundation for Applied Medical Research, ISCIII-Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional 'Una manera de hacer Europa' (PI19/00230 to AC, PI19/00098 to LMM, PI17/00411 to RP and DA, PI19/00560 to JMGP; CIBERONC CB16/12/00443 to LMM and CB16/12/00390 to JMGP), AECC and Ramón Areces Foundations (both to LMM), 'Instituto de Investigación Sanitaria del Principado de Asturias to JMGP and BMS (to JA and LMM).
dc.description.statementofresponsibilityRedin, E., Garmendia, I., Lozano, T., Serrano, D., Senent, Y., Redrado, M., Villalba, M., De Andrea, C.E., Exposito, F., Ajona, D., Ortiz-Espinosa, S., Remirez, A., Bertolo, C., Sainz, C., Garcia-Pedrero, J., Pio, R., Lasarte, J., Agorreta, J., Montuenga, L.M., Calvo, A.
dc.language.isoeng
dc.relation.ispartofJournal for ImmunoTherapy of Cancer
dc.rights© 2021 Los autores
dc.rightsCC Reconocimiento - No Comercial 4.0
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScopus
dc.source.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85102052429&doi=10.1136%2fjitc-2020-001496&partnerID=40&md5=fa5452e57cc27fa58db4dc7179ac0045
dc.titleSRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
dc.typejournal article
dc.identifier.doi10.1136/jitc-2020-001496
dc.relation.projectIDISCIII/PI19/00230
dc.relation.projectIDISCIII/PI19/00098
dc.relation.projectIDISCIII/PI17/00411
dc.relation.projectIDISCIII/PI19/00560
dc.relation.projectIDISCIII/CB16/12/00443
dc.relation.publisherversionhttp://dx.doi.org/10.1136/jitc-2020-001496
dc.rights.accessRightsopen access
dc.type.hasVersionVoR


Files in this item

untranslated
Name:
e001496.full.pdf
Size:
7.350Mb
Format:
PDF
Description:
Versión de la editorial

This item appears in the following Collection(s)

Show simple item record

© 2021 Los autores
This item is protected with a Creative Commons License